Influenzavirus B Infections - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Influenzavirus B Infections - Pipeline Review, H1 2018, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights

Influenzavirus B Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 16, 3, 4, 1, 10 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 129 pages “Influenzavirus B Infections - Pipeline Review, H1 2018” report covers Introduction, Influenzavirus B Infections - Overview, Influenzavirus B Infections - Therapeutics Development, Influenzavirus B Infections - Therapeutics Assessment, Influenzavirus B Infections - Drug Profiles, Influenzavirus B Infections - Dormant Projects, Appendix. This report Covered Companies few are - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp, AusBio Ltd, BioCryst Pharmaceuticals Inc, Biotron Ltd, Cadila Healthcare Ltd, ContraFect Corp, Daiichi Sankyo Co Ltd, Emergent BioSolutions Inc.

Please visit this link for more details: http://mrr.cm/Uej

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeH

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeV

Pseudomonas aeruginosa Pneumonia - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Pseudomonas aeruginosa Pneumonia - Pipeline Review, H1 2018, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights

Pseudomonas aeruginosa Pneumonia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Pneumonia (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 36 pages “Pseudomonas aeruginosa Pneumonia - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Pseudomonas aeruginosa Pneumonia - Overview, Pseudomonas aeruginosa Pneumonia - Therapeutics Development, Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment, Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development, Pseudomonas aeruginosa Pneumonia - Drug Profiles, Pseudomonas aeruginosa Pneumonia - Dormant Projects, Appendix. This report Covered Companies - Aridis Pharmaceuticals LLC, Emergent BioSolutions Inc, MedImmune LLC, Polyphor Ltd.

Please visit this link for more details: http://mrr.cm/Ue9

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeC

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsV

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

Report Highlights

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 55 pages “Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Systemic Idiopathic Juvenile Arthritis - Overview, Systemic Idiopathic Juvenile Arthritis - Therapeutics Development, Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment, Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development, Systemic Idiopathic Juvenile Arthritis - Drug Profiles, Systemic Idiopathic Juvenile Arthritis - Dormant Projects, Appendix. This report Covered Companies - Alteogen Inc, Johnson & Johnson, Livzon Pharmaceutical Group Inc, Mycenax Biotech Inc, Novartis AG, Oncobiologics Inc.

Please visit this link for more details: http://mrr.cm/Uey

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeC

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsV

Male Infertility - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Male Infertility - Pipeline Review, H1 2018, provides an overview of the Male Infertility (Male Health) pipeline landscape.

Male infertility refers to a male's inability to achieve a pregnancy in a fertile female. Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

Report Highlights

Male Infertility - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
• The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 37 pages “Male Infertility - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Male Infertility - Overview, Male Infertility - Therapeutics Development, Male Infertility - Therapeutics Assessment, Male Infertility - Companies Involved in Therapeutics Development, Male Infertility - Drug Profiles, Male Infertility - Dormant Projects, Appendix. This report Covered Companies - Cadila Healthcare Ltd, Ferring International Center SA, Health Ever Bio-Tech Co Ltd, Navya Biologicals Pvt Ltd.

Please visit this link for more details: http://mrr.cm/Uer

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeH

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UeV

West Nile Virus Infections - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

West Nile Virus Infections - Pipeline Review, H1 2018, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

Report Highlights

West Nile Virus Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 7 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 67 pages “West Nile Virus Infections - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, West Nile Virus Infections - Overview, West Nile Virus Infections - Therapeutics Development, West Nile Virus Infections - Therapeutics Assessment, West Nile Virus Infections - Companies Involved in Therapeutics Development, West Nile Virus Infections - Drug Profiles, West Nile virus vaccine - Drug Profile, West Nile Virus Infections - Dormant Projects, Appendix. This report Covered Companies - CEL-SCI Corp, Ennaid Therapeutics LLC, Hawaii Biotech Inc, Hemispherx Biopharma Inc, Kineta Inc, Ology Bioservices Inc, Plex Pharmaceuticals Inc.

Please visit this link for more details: http://mrr.cm/Usj

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Herpes Zoster (Shingles) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsH

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsV

Global Liquid Biopsy Market is expected to reach $8,730.4 million by 2024; Finds New Report

Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

Liquid biopsy global market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.

The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.

The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.

The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.

The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of $1,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Spanning over 496 pages “Liquid Biopsy Global Market - Forecast to 2024” report covers Executive Summary, Introduction, Market Analysis, Market Sizing, Liquid Biopsy Global Market, By Biomarker, Liquid Biopsy Global Market, By Application, Liquid Biopsy Global Market, By Sample, Liquid Biopsy Global Market,  By End-Users, Regional Analysis, Competitive Landscape, Major Companies. This Report Covered 125 Companies Few Are - Bgi, Biocept, Inc., Caredx, Inc., Cynvenio Biosystems, Inc., Eurofins Scientific Se, Exact Sciences Corporation, Exosome Diagnostics, Guardant Health, Inc., Illumina, Inc., Immucor, Inc.

Please visit this link for more details: http://mrr.cm/Usa

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Mild Cognitive Impairment - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Mild Cognitive Impairment - Pipeline Review, H1 2018, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Mild Cognitive Impairment - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 10, 6, 1 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 120 pages “Mild Cognitive Impairment - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Mild Cognitive Impairment - Overview, Mild Cognitive Impairment - Therapeutics Development, Mild Cognitive Impairment - Therapeutics Assessment, Mild Cognitive Impairment - Companies Involved in Therapeutics Development, Mild Cognitive Impairment - Drug Profiles, Mild Cognitive Impairment - Dormant Projects, Appendix. This report Covered Companies - AbbVie Inc, AgeneBio Inc, Avraham Pharmaceuticals Ltd, Biogen Inc, CereSpir Inc, Eisai Co Ltd, Eli Lilly and Co, Genzyme Corp, IntelGenx Corp, Krenitsky Pharmaceuticals Inc, Neuron Biopharma SA, Octapharma AG, Pfizer Inc, Sage Therapeutics Inc, SBI Pharmaceuticals Co Ltd, Suven Life Sciences Ltd, Takeda Pharmaceutical Co Ltd, Therapix Biosciences Ltd.

Please visit this link for more details: http://mrr.cm/Usr

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Herpes Zoster (Shingles) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsH

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UsV